

# A Funded Clinical Trial for Dogs with Lymphoma

A new clinical trial option is open for dogs with lymphoma, the most common cancer diagnosed and treated in veterinary practice.

## Trial Summary

An estimated 18 client-owned pet dogs will be enrolled in this Phase I study. The study is an open-label, single agent, dose escalation study of a novel anti-cancer agent in dogs with lymphoma.

The study involves diagnostic testing (multiple blood sample collections and biopsies) along with administration of the study medication during a 1-week study period. After the 1-week study, dogs are eligible to receive standard care for lymphoma at the discretion of the veterinarian and dog owner.

## Trial Support and Funding

The study is fully funded for 1-week study duration. Upon completion of the study, the study will pay \$2000 for each patient enrolled to be used for costs associated with oncology care. The study will also pay for the management of side effects to the study medication (should they occur in the 1-week study period).

## Trial Eligibility

Inclusion Criteria:

- Client-owned pet dogs
- Informed owner consent prior to initiation of screening/treatment
- Naïve or relapsed Lymphoma
- Lymphoma Stages II-V – substage a only (must have at least one target lymph node  $\geq 2$  cm longest diameter on physical exam)
- Cytological or histological diagnosis of Lymphoma
- Favorable Performance Score 0-1 (based on Modified Eastern Cooperative Oncology Group Performance Score)

Exclusion Criteria:

- Dogs with a concurrent medical disorder likely to result in death or euthanasia within 4 months or a condition which may be disruptive to the intent and objectives of the study
- Anticipated poor owner compliance
- Lymphoma Stage I or Substage B
- Dogs < 5 kg
- Dogs that are pregnant or likely to become pregnant
- Dogs that are participating in another clinical trial

- Dogs that will be unavailable for the duration of the trial or that are felt to be unsuitable by the Investigator for any other reason
- Chemotherapy within 21 days of the enrollment visit
- Prednisone treatment within 7 days of the enrollment visit
- Treatment with hormonal, immunotherapy, biological therapy, and/or small molecule inhibitors within 21 days of the enrollment visit
- Treatment with radiation therapy within 30 days of the enrollment visit